Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
36.36
-0.26 (-0.71%)
At close: Sep 4, 2026, 4:00 PM EDT
37.19
+0.83 (2.28%)
After-hours: Sep 4, 2026, 7:59 PM EDT
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.14B in the quarter ending June 30, 2026, a decrease of -0.81%. This brings the company's revenue in the last twelve months to $17.32B, up 4.13% year-over-year. In the year 2025, Teva Pharmaceutical had annual revenue of $17.26B with 4.32% growth.
Revenue (ttm)
$17.32B
Revenue Growth
+4.13%
P/S Ratio
2.45
Revenue / Employee
$510,015
Employees
33,950
Market Cap
42.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.42B |
| Haleon | 14.80B |
| Viatris | 14.74B |
| Zoetis | 9.53B |
| Elanco Animal Health | 5.02B |
| Dr. Reddy's Laboratories | 3.50B |
| Neurocrine Biosciences | 3.37B |
| United Therapeutics | 3.15B |
TEVA News
- 12 hours ago - S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline - GlobeNewsWire
- 18 hours ago - Teva price target raised to $48 from $42 at UBS - TheFly
- 1 day ago - Biotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive Gains - Nasdaq
- 2 days ago - A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.6% Gain -- GF Value $20. ... - GuruFocus
- 2 days ago - Teva's TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study - MarketBeat
- 2 days ago - Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease - Nasdaq
- 2 days ago - TEVA Looks 74.7% Overvalued on GF Value⢠as Phase 2a Trial Data Emerges - GuruFocus
- 2 days ago - TEVA Looks 74.7% Overvalued on GF Value⢠as Positive Trial News Boosts Sentiment - GuruFocus